Biotech companies with novel molecules in clinical development require substantial sums of cash to finance that research. While venture capital firms continue to raise new funds to deploy across such investments, many companies that successfully landed financing a few years ago find it harder to raise money now.
Chris Garabedian, chairman and CEO of Xontogeny and venture portfolio manager of the Perceptive Advisors Xontogeny Ventures Fund, remembers that bullish time for biotech…
Read More…
Two Venture Investors Offer Their Takes on the State of Biotech Investing Today
